Breaking News Instant updates and real-time market news.

AGN

Allergan

$227.55

-4.81 (-2.07%)

, VTAE

Vitae Pharmaceuticals

$20.99

0.02 (0.10%)

08:02
10/17/16
10/17
08:02
10/17/16
08:02

Allergan, Vitae Pharmaceuticals announce expiration of HSR waiting period

Allergan (AGN) and Vitae Pharmaceuticals (VTAE) announced that the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, has expired with respect to Allergan's pending acquisition of Vitae. The expiration of the HSR waiting period satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions. Both companies expect the transaction to be completed in the fourth quarter.

AGN

Allergan

$227.55

-4.81 (-2.07%)

VTAE

Vitae Pharmaceuticals

$20.99

0.02 (0.10%)

  • 26

    Oct

  • 02

    Nov

  • 06

    Nov

AGN Allergan
$227.55

-4.81 (-2.07%)

09/21/16
GABE
09/21/16
NO CHANGE
GABE
Buy
Gabelli questions if Allergan could target Gilead next
Gabelli analyst Kevin Kedra said that "like most" he was surprised at the price paid and the strategic fit of Allergan's (AGN) deal to buy Tobira Therapeutics (TBRA), but wonders if Allergan CEO Brent Saunders is "playing chess while the market is playing checkers" and could be preparing a bid for Gilead (GILD). After Allergan's "very loud statement about its commitment to NASH and liver disease," a deal for Gilead, the leading company in liver disease and "one of the cheapest companies in pharma/biotech," would appear to make more sense, Kedra tells investors, adding that an acquisition of Gilead at a price of $115 per share would be "highly accretive" for Allergan. The analyst keeps a Buy rating on Allergan shares.
09/22/16
BERN
09/22/16
NO CHANGE
BERN
Allergan acquisitions positive, says Bernstein
After Allergan bought two companies with NASH drugs and the stock fell, Bernstein analyst Aaron Gal says the acquisitions were viewed as expensive. Gal says "it makes almost no difference" if the deals were expensive, as the important issue is whether the products succeed. He believes that the market would never penalize Roche or Celgene for similar deals, and he thinks this indicates that Allergan is "misvalued." He says that Allergan is his "high conviction buy" stock and keeps a $335 price target on the shares.
09/26/16
LEER
09/26/16
NO CHANGE
LEER
Shire Xiidra launch to 'significantly' expand dry eye category, says Leerink
Leerink analyst Jason Gerberry remains optimistic that Shire's (SHPG) Xiidra launch will "significantly" expand the category for dry eye disease brands, while not meaningfully eroding Allergan's (AGN) Restasis market leading position. While it's still early in the launch of Xiidra and payer access remains a critical variable, the analyst does not anticipate access being a major barrier. Gerberry reiterates an Outperform rating on both Shire and Allergan's shares.
10/14/16
LEER
10/14/16
NO CHANGE
Target $294
LEER
Outperform
Leerink positive on Allergan ahead of Restasis patent decision
Leerink analyst Jason Gerberry is positive on Allergan's franchise outlook as he believes the company will either maintain a double-digit top-line" growth pharma" trajectory or alternatively institute a dividend, and will prevail in the ongoing Restasis patent challenge. Gerberry likes Allergan's underlying growth trends of the gastro and derm franchises and pipeline optionality, and reiterates an Outperform rating and $294 price target on the shares.
VTAE Vitae Pharmaceuticals
$20.99

0.02 (0.10%)

09/15/16
BMOC
09/15/16
DOWNGRADE
BMOC
Market Perform
Vitae Pharmaceuticals downgraded to Market Perform at BMO Capital
Vitae Pharmaceuticals (VTAE) has agreed to be acquired by Allergan (AGN) for $21 per share in cash.
09/15/16
WELS
09/15/16
DOWNGRADE
WELS
Market Perform
Vitae downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough downgraded Vitae Pharmaceuticals (VTAE) to Market Perform following the proposed acquisition of Allergan (AGN). The deal's valuation is "relatively cheap and leaves open some possibility of a competing bid and modest price bump," Birchenough tells investors in a research note. He lowered his price target range for the shares to $21-$27 from $27-$32.
09/15/16
JMPS
09/15/16
NO CHANGE
JMPS
Kadmon has positive read through from Allergan deal, says JMP Securities
JMP Securities analyst Michael King says that Allergan's (AGN) acquisition of Vitae Pharmaceuticals (VTAE) bodes well for Kadmon's (KDMN) ROCK inhibitor KD025 for patients with psoriasis. The analyst says that the main driver for the Vitae deal was its oral RORyt inhibitor VTP-43742 which could become a psoriasis treatment. There are "mechanistic similarities" between Vitae's drug and Kadmon's psoriasis drug candidate KD025, King wrote. He reiterates a $16 price target and Outperform rating on Kadmon.
09/20/16
PIPR
09/20/16
DOWNGRADE
PIPR
Neutral
Vitae Pharmaceuticals downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff downgraded Vitae Pharmaceuticals (VTAE) to Neutral citing Allergan's (AGN) takeover of the company. The analyst does not expect other offers to emerge.

TODAY'S FREE FLY STORIES

RHHBY

Roche

$27.67

0.47 (1.73%)

20:25
12/05/16
12/05
20:25
12/05/16
20:25
Conference/Events
Roche to hold an analyst meeting »

Analyst Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

AZO

AutoZone

$776.42

-7.32 (-0.93%)

, HDS

HD Supply

$39.75

0.67 (1.71%)

20:25
12/05/16
12/05
20:25
12/05/16
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

AZO

AutoZone

$776.42

-7.32 (-0.93%)

HDS

HD Supply

$39.75

0.67 (1.71%)

MIK

Michaels

$24.31

0.34 (1.42%)

TOL

Toll Brothers

$30.47

1.15 (3.92%)

BOBE

Bob Evans

$46.77

1.05 (2.30%)

CONN

Conn's

$11.20

0.4 (3.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 14

    Dec

  • 09

    Jan

GDDY

GoDaddy

$34.74

1.45 (4.36%)

20:14
12/05/16
12/05
20:14
12/05/16
20:14
Hot Stocks
GoDaddy acquires WP Curve »

WP Curve announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDC

Belden

$74.99

0.9 (1.21%)

20:10
12/05/16
12/05
20:10
12/05/16
20:10
Earnings
Belden sees FY17 adjusted EPS $5.00-$5.25, consensus $5.23 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SGMO

Sangamo

19:39
12/05/16
12/05
19:39
12/05/16
19:39
Hot Stocks
Sangamo reports preclinical, manufacturing data on SB-525, says IND on track »

Sangamo BioSciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SGEN

Seattle Genetics

$66.26

-0.44 (-0.66%)

, BMY

Bristol-Myers

$55.55

-0.41 (-0.73%)

19:38
12/05/16
12/05
19:38
12/05/16
19:38
Hot Stocks
Seattle Genetics, Bristol-Myers: Data supports ADCETRIS, Opdivo combo »

Seattle Genetics (SGEN)…

SGEN

Seattle Genetics

$66.26

-0.44 (-0.66%)

BMY

Bristol-Myers

$55.55

-0.41 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

LGIH

LGI Homes

$32.34

0.45 (1.41%)

19:36
12/05/16
12/05
19:36
12/05/16
19:36
Hot Stocks
LGI Homes reports November home closings up 28.9% y/y »

LGI Homes announced 321…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$116.56

-1.07 (-0.91%)

19:36
12/05/16
12/05
19:36
12/05/16
19:36
Hot Stocks
Celgene reports analysis of three CC-486 studies »

Celgene announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

BLUE

bluebird bio

$72.15

2.4 (3.44%)

19:35
12/05/16
12/05
19:35
12/05/16
19:35
Hot Stocks
bluebird bio provides updates on HSC gene therapy programs »

bluebird bio provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$49.88

-7.09 (-12.45%)

19:33
12/05/16
12/05
19:33
12/05/16
19:33
Hot Stocks
Agios 'encouraged' by durable clinical activity of AG-120 »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$60.25

-0.88 (-1.44%)

19:31
12/05/16
12/05
19:31
12/05/16
19:31
Hot Stocks
Merck: KEYNOTE-087 trial data shows oORR of 69%, CRR of 22.4% »

Merck announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 08

    Mar

TWX

Time Warner

$93.34

-0.46 (-0.49%)

, T

AT&T

$38.63

0.02 (0.05%)

19:29
12/05/16
12/05
19:29
12/05/16
19:29
Periodicals
Time Warner 'struggling to expand' HBO Now, NY Post says »

Time Warner (TWX) is…

TWX

Time Warner

$93.34

-0.46 (-0.49%)

T

AT&T

$38.63

0.02 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

BP

BP

, REPYY

Repsol

$13.88

0.25 (1.83%)

19:18
12/05/16
12/05
19:18
12/05/16
19:18
Periodicals
BP acquires Repsol stake in Indonesia LNG plant, Reuters says »

BP (BP) has purchased…

BP

BP

REPYY

Repsol

$13.88

0.25 (1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOSUF

Fosun

19:12
12/05/16
12/05
19:12
12/05/16
19:12
Hot Stocks
Liberty Mutual to acquire Fosun subsidiary Ironshore for roughly $3B »

Liberty Mutual Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$49.75

-0.06 (-0.12%)

, YHOO

Yahoo

$40.20

0.13 (0.32%)

18:54
12/05/16
12/05
18:54
12/05/16
18:54
Periodicals
AOL CEO 'cautiously optimistic' Verizon-Yahoo deal will go through, WSJ says »

AOL CEO Tim Armstrong…

VZ

Verizon

$49.75

-0.06 (-0.12%)

YHOO

Yahoo

$40.20

0.13 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 24

    Jan

TUWOY

Tullow Oil

$2.06

0.109 (5.58%)

18:46
12/05/16
12/05
18:46
12/05/16
18:46
Downgrade
Tullow Oil rating change  »

Tullow Oil downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBNK

Guaranty Bancorp

$22.15

0.75 (3.50%)

18:43
12/05/16
12/05
18:43
12/05/16
18:43
Hot Stocks
Breaking Hot Stocks news story on Guaranty Bancorp »

Castle Creek raises stake…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATKR

Atkore

$20.48

-0.18 (-0.87%)

18:41
12/05/16
12/05
18:41
12/05/16
18:41
Syndicate
Atkore files to sell 8M shares of common stock for holders »

The offering is being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$107.42

-0.8 (-0.74%)

18:38
12/05/16
12/05
18:38
12/05/16
18:38
Hot Stocks
United Technologies CEO: No quid pro quo on taxes in Carrier deal with Trump »

Says Carrier agreement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPDN

Professional Diversity Network

$9.75

-0.01 (-0.10%)

18:37
12/05/16
12/05
18:37
12/05/16
18:37
Hot Stocks
Breaking Hot Stocks news story on Professional Diversity Network »

North Star cuts passive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHXM

DHX Media

$5.05

-0.36 (-6.65%)

18:33
12/05/16
12/05
18:33
12/05/16
18:33
Hot Stocks
Breaking Hot Stocks news story on DHX Media »

Luxor Capital cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPHS

Trinity Place

$10.02

0.08 (0.80%)

18:24
12/05/16
12/05
18:24
12/05/16
18:24
Hot Stocks
Trinity Place Holdings, Pacolet Milliken acquire Brooklyn building for $68.8M »

Trinity Place Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SU

Suncor

$32.46

0.23 (0.71%)

18:07
12/05/16
12/05
18:07
12/05/16
18:07
Hot Stocks
Suncor Energy resolves C$1.3B tax dispute with Canada Revenue Agency »

Suncor Energy reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRN

Acceleron

$34.90

-1.39 (-3.83%)

, CELG

Celgene

$116.56

-1.07 (-0.91%)

18:07
12/05/16
12/05
18:07
12/05/16
18:07
Hot Stocks
Acceleron, Celgene report Phase 2 data on luspatercept in beta-thalassemia »

Acceleron Pharma (XLRN)…

XLRN

Acceleron

$34.90

-1.39 (-3.83%)

CELG

Celgene

$116.56

-1.07 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

SNSS

Sunesis

$4.02

0.12 (3.08%)

17:54
12/05/16
12/05
17:54
12/05/16
17:54
Hot Stocks
Sunesis says new VALOR trial data show 'compelling durable survival outcomes' »

Sunesis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.